Cellular Effects of Everolimus and Sirolimus on Podocytes

Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection. However, some patients develop proteinuria following a switch from a calcineurin inhibitor regimen to mTOR inhibitors. Whether different mTOR inhibitors show similar effects on podocytes is still unknown. To analyze this, human podocytes were incubated with different doses of EVL and SRL. After incubation with EVL or SRL, podocytes revealed a reduced expression of total mTOR. Phosphorylation of p70S6K and Akt was diminished, whereas pAkt expression was more reduced in the SRL group. In both groups actin cytoskeletal reorganization was increased. Synaptopodin and podocin expression was reduced as well as nephrin protein, particularly in the SRL group. NFκB activation and IL-6 levels were lower in EVL and SRL, and even lower in SRL. Apoptosis was more increased in SRL than in the EVL group. Our data suggests that mTOR inhibitors affect podocyte integrity with respect to podocyte proteins, cytoskeleton, inflammation, and apoptosis. Our study is the first to analyze both mTOR inhibitors, EVL and SRL, in parallel in podocytes. Partially, the impact of EVL and SRL on podocytes differs. Nevertheless, it still remains unclear whether these differences are of relevance regarding to proteinuria in transplant patients.

[1]  R. Bashir,et al.  Growth Factors , 1996 .

[2]  T. Shokati,et al.  Everolimus and Sirolimus in Combination with Cyclosporine Have Different Effects on Renal Metabolism in the Rat , 2012, PloS one.

[3]  T. Madhusudhan,et al.  Human RAGE antibody protects against AGE-mediated podocyte dysfunction. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  C. Esmon,et al.  Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. , 2012, Blood.

[5]  G. Rábago,et al.  Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients. , 2011, Transplantation proceedings.

[6]  C. Legendre,et al.  The ORION Study: Comparison of Two Sirolimus‐Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  E. Thervet,et al.  Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four‐Year Results of the Postconcept Study , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Sampaio,et al.  Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin‐free regimen , 2011, Clinical transplantation.

[9]  H. Hammes,et al.  Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. , 2011, Journal of the American Society of Nephrology : JASN.

[10]  Thomas Becker,et al.  Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.

[11]  B. Meier,et al.  Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. , 2010, Transplant immunology.

[12]  R. Munivenkatappa,et al.  Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF. , 2010, Histology and histopathology.

[13]  R. Abraham,et al.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. , 2009, Seminars in oncology.

[14]  H. Pavenstädt,et al.  mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. , 2009, American journal of physiology. Renal physiology.

[15]  E. Letavernier,et al.  Sirolimus interacts with pathways essential for podocyte integrity. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[17]  L. Rostaing,et al.  Prospective Comparison of the Use of Sirolimus and Cyclosporine in Recipients of a Kidney From an Expanded Criteria Donor , 2008, Transplantation.

[18]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[19]  M. Nangaku,et al.  Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. , 2007, Kidney international.

[20]  T. Takenawa,et al.  Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. , 2007, The American journal of pathology.

[21]  E. Letavernier,et al.  High sirolimus levels may induce focal segmental glomerulosclerosis de novo. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[22]  R. Pearson,et al.  Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.

[23]  C. Daniel,et al.  Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  S. Shankland,et al.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.

[25]  Yasuhiko Tomino,et al.  Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling , 2006, Nature Cell Biology.

[26]  F. Keller,et al.  Resolution of sirolimus-induced pneumonitis after conversion to everolimus. , 2006, Transplantation proceedings.

[27]  R. Miller,et al.  WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. , 2005, American journal of physiology. Renal physiology.

[28]  K. Asanuma,et al.  Synaptopodin regulates the actin-bundling activity of α-actinin in an isoform-specific manner , 2005 .

[29]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[30]  K. Asanuma,et al.  Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. , 2005, The Journal of clinical investigation.

[31]  R. Kalluri,et al.  Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.

[32]  A. Keogh.  Calcineurin inhibitors in heart transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  E. Milford,et al.  Renal insufficiency and end-stage renal disease in the heart transplant population. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[35]  E. Morelon,et al.  Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. , 2003, Transplantation proceedings.

[36]  B. Nashan.  Review of the proliferation inhibitor everolimus , 2002, Expert opinion on investigational drugs.

[37]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[38]  M. O'hare,et al.  A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. , 2002, Journal of the American Society of Nephrology : JASN.

[39]  T. Benzing,et al.  Interaction with Podocin Facilitates Nephrin Signaling* , 2001, The Journal of Biological Chemistry.

[40]  G. Camussi,et al.  Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. , 2001, The American journal of pathology.

[41]  M. Manns,et al.  Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. , 2000, British journal of clinical pharmacology.

[42]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[43]  B. Kahan,et al.  Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration , 1997, Journal of clinical pharmacology.

[44]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[45]  R. Lannigan.  Puromycin aminonucleoside nephrosis in rats: a progress report of acute and chronic experiments. , 1962, Guy's Hospital reports.